Genetic predictors of efficacy and toxicity of iguratimod in patients with rheumatoid arthritis

Pharmacogenomics. 2018 Apr;19(5):383-392. doi: 10.2217/pgs-2017-0162. Epub 2018 Mar 8.

Abstract

Iguratimod (IGU) is a novel disease-modifying anti-rheumatic drug (DMARD) in rheumatoid arthritis (RA). Like other DMARDs, IGU exhibited significant differences in effectiveness and safety.

Aim: The aim of this study was to identify genetic predictorsof efficacyand toxicity of IGU in patients with RA.

Materials & methods: Seven SNPs from IGU-metabolizing genes were genotyped in 272 IGU-treated patients with RA. Results: ABCG2 rs2231142 A allele conferred a higher response to IGU, while NAT2 rs1495742 G carriersconferred a lower response to IGU. CYP2C19*2 rs4244285 A carriers had higher risk for IGU-induced toxicity compared to the GG carriers.

Conclusion: Our study suggests that the polymorphisms of ABCG2 (rs2231142), NAT2 (rs1495741)and CYP2C19*2 (rs4244285) may help to predict thetherapeutic effectiveness and toxicity of IGU in patients with RA.

Keywords: efficacy; genetic predictors; iguratimod; rheumatoid arthritis; toxicity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antirheumatic Agents / adverse effects*
  • Antirheumatic Agents / metabolism
  • Antirheumatic Agents / therapeutic use*
  • Arthritis, Rheumatoid / drug therapy*
  • Arthritis, Rheumatoid / genetics*
  • China
  • Chromones / adverse effects*
  • Chromones / metabolism
  • Chromones / therapeutic use*
  • DNA / genetics
  • Female
  • Genetic Carrier Screening
  • Genotype
  • Heterozygote
  • Humans
  • Male
  • Middle Aged
  • Polymorphism, Single Nucleotide / genetics
  • Predictive Value of Tests
  • Risk Assessment
  • Sulfonamides / adverse effects*
  • Sulfonamides / metabolism
  • Sulfonamides / therapeutic use*

Substances

  • Antirheumatic Agents
  • Chromones
  • Sulfonamides
  • iguratimod
  • DNA